Contains Positive Control: Human skin fibroblast protein, supplied at 1mg/ml in SDS (Laemmli) sample buffer. Use 25μl (25μg) per lane for Western blotting.
Immunogen
Recombinant human lipoma preferred partner (LPP) (aa 1-109).
LPP
Reaktivität: Human
ELISA
Wirt: Kaninchen
Polyclonal
Biotin
Applikationshinweise
Use 25 μL (25 μg) per lane for Western blotting.
Beschränkungen
Nur für Forschungszwecke einsetzbar
Format
Liquid
Konzentration
Lot specific
Buffer
In PBS containing 0.01 % sodium azide.
Konservierungsmittel
Sodium azide
Vorsichtsmaßnahmen
This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
Lagerung
4 °C,-20 °C
Informationen zur Lagerung
Short Term Storage: +4°C Long Term Storage: -20°C Stable for at least 1 year after receipt when stored at -20°C.
Haltbarkeit
12 months
Target
LPP
(Lipoma-preferred partner (LPP))
Andere Bezeichnung
Lipoma Preferred Partner
Hintergrund
Lipoma preferred partner (LPP) is encoded by the preferred fusion partner gene of the high mobility group protein HMGI-C. LPP is frequently affected by chromosomal translocations in a major group of soft tissue lipomas, as well as in a parosteal lipoma and in pulmonary chondroid hamartomas. The resulting fusion proteins comprise three DNA binding domains of HMGI-C fused to two or three C-terminal LIM domains of LPP and a reciprocal product, respectively. Expression of a HMGI-C/LPP fusion protein causes malignant transformation of fibroblasts. Similar to its relatives zyxin and TRIP (thyroid receptor interacting protein 6) / ZRP-1 (zyxin-related protein 1), LPP consists of a N-terminal proline-rich domain followed by three C-terminal LIM domains (double zinc finger structures that are involved in protein-protein interactions). Like the cytoskeletal protein zyxin, LPP localizes to focal adhesions and cell-cell adherens junctions. LPP harbors a nuclear export signal and displays transcriptional activation capacity.